Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Minority Interest (2021 - 2025)

Oramed Pharmaceuticals filings provide 5 years of Minority Interest readings, the most recent being -$952000.0 for Q3 2025.

  • Quarterly Minority Interest fell 3.59% to -$952000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$952000.0 through Sep 2025, down 3.59% year-over-year, with the annual reading at -$918000.0 for FY2024, 1.08% up from the prior year.
  • Minority Interest hit -$952000.0 in Q3 2025 for Oramed Pharmaceuticals, down from -$946000.0 in the prior quarter.
  • Across five years, Minority Interest topped out at $744000.0 in Q3 2021 and bottomed at -$1.5 million in Q2 2021.
  • Average Minority Interest over 5 years is -$685722.2, with a median of -$906500.0 recorded in 2023.
  • The largest annual shift saw Minority Interest crashed 552.38% in 2023 before it rose 1.08% in 2024.
  • Oramed Pharmaceuticals' Minority Interest stood at $536000.0 in 2021, then crashed by 222.39% to -$656000.0 in 2022, then tumbled by 41.46% to -$928000.0 in 2023, then grew by 1.08% to -$918000.0 in 2024, then fell by 3.7% to -$952000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Minority Interest are -$952000.0 (Q3 2025), -$946000.0 (Q2 2025), and -$918000.0 (Q1 2025).